Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Upcoming events – Verona waits to exhale and a new test for Alexion
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Vertex’s triplet win leaves price the only question
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
Abbvie’s low-risk bet could challenge Vertex on price
The big pharma’s cystic fibrosis deal with Galapagos is greeted with surprise, but the gamble might actually make sense.
Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Upcoming events – Galapagos needs Falcon to fly, but Abbott risks having its wings clipped
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.